Investing Profile

Ken Belotsky

VC
Founding Partner at Negev Capital. Leading VC in psychedelic drug development
negevcap.comTel Aviv, Israel
Photo of Ken Belotsky, Managing Partner at Negev Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Negev Capital Managing Partner
$500K - $3.0M
$1M
6
CompanyStageDateRound SizeTotal Raised
Gilgamesh Pharmaceuticals
series BMay 2022$1
$2.1M
Co-investors: Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Dave Messina (Pioneer Fund), Rand Hindi
Mindstate Design Labs
Seed RoundFeb 2022$12M
$24M
Co-investors: Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Rand Hindi
Delix Therapeutics
Series ASep 2021$70M
$70M
Co-investors: Matias Serebrinsky (PsyMed Ventures)
Beckley Psytech
Series BAug 2021£58M
£58M
$1
Co-investors: Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Matias Serebrinsky (PsyMed Ventures)
ATAI Life Sciences
Series BMar 2019$43M
$220M
Co-investors: Maryanna Saenko (Future Ventures), Martin Alexander Gershon (Endeavor Venture Funds), Stephen Hays (What If Ventures), Matias Serebrinsky (PsyMed Ventures), Akshay Sriprasad
Small Pharma
Seed RoundApr 2017£830K
$1M
£830K
Co-investors: David Ebsworth